EU Probiotic Harmonisation Proposed; UK CBD & Claims Regulation Faces Scrutiny

Regulatory clarity for supplement manufacturers across Europe has undergone significant shifts. In 2023, the European Commission proposed an EU working group to harmonise the term 'probiotic' across Member States. This followed Austria's query regarding France's allowance of the term on food supplement labels, a practice not officially endorsed by the European Food Safety Authority (EFSA), which deemed it an unauthorised health claim. This initiative was critical for standardising market access and consumer communication for a category experiencing sustained growth and innovation.

In parallel, technological advancements have been reshaping product development. Biomdrin, a VeCollal subsidiary, launched an AI-powered tool capable of processing data on over 70,000 ingredients. This platform dramatically accelerates the formulation of scientifically-sound supplements by identifying complex interactions between diseases, genes, and ingredients, potentially reducing development timelines and the need for extensive in vitro testing. This innovation offers a strategic advantage for brands seeking rapid, validated product launches and improved R&D efficiency.

Commercial success continues to be driven by scientific substantiation. Health giant Haleon reported a 10.6% revenue increase year-on-year, attributing its 'Centrum' multivitamin brand's growth to robust clinical trials and scientific communication. This reinforces the critical role of clinical research in building brand credibility and consumer trust in a competitive market. Further demonstrating strategic brand positioning, VOW Nutrition partnered with Team GB as the Official Nutrition Licensee for the Paris 2024 Olympic games, leveraging elite athlete endorsement to validate its sports nutrition range.

The UK supplement market has faced specific regulatory challenges. The Association for the Cannabinoid Industry (ACI) pressured the UK Home Office to establish clear THC limits for CBD products. This urgency stemmed from the revocation of Jersey Hemp's export license, which highlighted the precarious position of CBD brands operating without a standardised testing methodology or an agreed legal THC threshold. The ACI warned that the lack of clarity had stalled the CBD Novel Foods process, exposing companies to legal risks during market authorisation efforts.

Additionally, the UK Office for Health Improvements and Disparities (OHID) introduced proposals for enhancing adherence to health and nutrition claim regulations, including 'improvement notices' for non-compliant food companies. However, industry experts expressed scepticism regarding their impact, noting minimal past prosecution efforts and the likelihood that local authorities would continue to defer enforcement to the Advertising Standards Authority (ASA). This suggested that while regulatory intent existed, practical enforcement mechanisms might remain unchanged, requiring manufacturers to maintain vigilance against ASA rulings rather than new government penalties.

What this means for the United Kingdom

UK manufacturers must prepare for potential changes in EU export requirements for probiotics if the working group introduces new harmonised standards, necessitating reformulation or updated labelling for access to the single market. Domestically, the lack of a clear THC limit for CBD products represents a significant commercial risk; brands should audit their supply chains and product specifications to mitigate potential Home Office enforcement actions. OHID's claim proposals suggest continued reliance on the ASA for enforcement, meaning brands must ensure all marketing claims meet ASA guidelines to avoid costly disputes and reputational damage. Investment in AI formulation tools could provide a competitive edge in rapid, scientifically-backed product development, crucial for market differentiation.

Many leading brands in this category are manufactured in partnership with Supplement Factory.